NEW YORK (GenomeWeb) – Selah Genomics, a subsidiary of EKF Diagnostics, today announced a collaboration with Greenville Health System, DecisionQ, and Becton Dickinson to integrate next-generation sequencing into the care of colon cancer patients.

As part of the 18-month partnership, Selah Genomics will use its PrecisionPath NGS technology to profile tumor samples provided by the Institute for Translational Oncology Research (ITOR), part of GHS's Cancer Institute. The samples, from colon cancer patients, will be provided with full clinical annotation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Sponsored by

This webinar will describe a protocol and proof-of-principle experiments for Cellular Indexing of Transcriptome and Epitopes by Sequencing (CITE-seq).

Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs. 

Sponsored by

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.